Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Surfactant protein A1 (SFTPA1) is a lung-specific, secreted protein within the collectin family of C-type lectins, mainly produced by alveolar type II epithelial cells. It plays an essential role in maintaining surfactant homeostasis by reducing surface tension at the air-liquid interface in the lung alveoli, supporting normal respiration. In addition, SFTPA1 is a soluble pattern-recognition receptor that binds to specific carbohydrate- and lipid-containing moieties on pathogens, facilitating their opsonization and clearance by immune cells, especially alveolar macrophages, and contributing to the regulation of inflammatory and immune responses in the lungs. SFTPA1 mutations and regulatory variant differences are linked to lung diseases including idiopathic pulmonary fibrosis, interstitial lung disease, pulmonary infections, and some lung cancers, where its genetic and epigenetic regulation may serve as a biomarker of disease susceptibility and progression.
Drug interactions are not well-characterized; no approved therapeutics directly target SFTPA1. Experimental modulation includes transcriptional induction or inhibition (e.g., glucocorticoids down-regulate expression).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Surfactant protein A1 (SFTPA1).